Kessler R M, Ansari M S, Schmidt D E, de Paulis T, Clanton J A, Innis R, al-Tikriti M, Manning R G, Gillespie D
Department of Radiology, Vanderbilt University School of Medicine, Nashville, TN 37232.
Life Sci. 1991;49(8):617-28. doi: 10.1016/0024-3205(91)90261-9.
Epidepride, (S)-N-[(1-ethyl-2-pyrrolidinyl)methyl]-5-iodo-2,3-dimethoxybenzamide+ ++, the iodine analogue of isoremoxipride (FLB 457), was found to be a very potent dopamine D2 receptor antagonist. Optimal in vitro binding required incubation at 25 degrees C for 4 h at pH 7.4 in a buffer containing 120 mM NaCl, 5 mM KCl, 2 mM CaCl2 and 1 mM MgCl2. Scatchard analysis of in vitro binding to striatal, medial frontal cortical, hippocampal and cerebellar membranes revealed a KD of 24 pM in all regions, with Bmax's of 36.7, 1.04, 0.85, and 0.37 pmol/g tissue, respectively. The Hill coefficients ranged from 0.91-1.00 in all four regions. The IC50's for inhibition of [125I]epidepride binding to striatal, medial frontal cortical, and hippocampal membranes for SCH 23390, SKF 83566, serotonin, ketanserin, mianserin, naloxone, QNB, prasozin, clonidine, alprenolol, and norepinephrine ranged from 1 microM to greater than 10 microM. Partial displacement of [125I]epidepride by nanomolar concentrations of clonidine was noted in the frontal cortex and hippocampus, but not in the striatum. Scatchard analysis of epidepride binding to alpha 2 noradrenergic receptors in the frontal cortex and hippocampus revealed an apparent KD of 9 nM. At an epidepride concentration equal to the KD for the D2 receptor, i.e. 25 pM, no striatal alpha 2 binding was seen and only 7% of the specific epidepride binding in the cortex or hippocampus was due to binding at the alpha 2 site. Correlation of inhibition of [3H]spiperone and [125I]epidepride binding to striatal membranes by a variety of D2 ligands revealed a correlation coefficient of 0.99, indicating that epidepride labels a D2 site. In vitro autoradiography revealed high densities of receptor binding in layers V and VI of prefrontal and cingulate cortices as well as in striatum. In vivo rat brain uptake revealed a hippocampal:cerebellar and frontal cortical:cerebellar ratio of 2.2:1 which fell to 1.1:1 following haloperidol pretreatment. These properties suggest that [125I]epidepride is a superior radioligand for the in vitro and in vivo study of striatal and extrastriatal dopamine D2 receptors.
表阿必利,(S)-N-[(1-乙基-2-吡咯烷基)甲基]-5-碘-2,3-二甲氧基苯甲酰胺+++,异雷莫必利(FLB 457)的碘类似物,被发现是一种非常有效的多巴胺D2受体拮抗剂。体外最佳结合需要在含有120 mM氯化钠、5 mM氯化钾、2 mM氯化钙和1 mM氯化镁的缓冲液中,于25℃、pH 7.4条件下孵育4小时。对纹状体、内侧额叶皮质、海马体和小脑膜进行体外结合的Scatchard分析显示,所有区域的KD为24 pM,Bmax分别为36.7、1.04、0.85和0.37 pmol/g组织。所有四个区域的希尔系数范围为0.91 - 1.00。SCH 23390、SKF 83566、5-羟色胺、酮色林、米安色林、纳洛酮、QNB、哌唑嗪、可乐定、阿普洛尔和去甲肾上腺素对[125I]表阿必利与纹状体、内侧额叶皮质和海马体膜结合的IC50范围为1 μM至大于10 μM。在额叶皮质和海马体中,纳摩尔浓度的可乐定可部分置换[125I]表阿必利,但在纹状体中未出现这种情况。对表阿必利与额叶皮质和海马体中α2去甲肾上腺素能受体结合的Scatchard分析显示,表观KD为9 nM。在表阿必利浓度等于D2受体的KD(即25 pM)时,未观察到纹状体α2结合,而在皮质或海马体中,仅7%的特异性表阿必利结合是由于在α2位点的结合。多种D2配体对[3H]螺哌隆和[125I]表阿必利与纹状体膜结合的抑制作用的相关性显示,相关系数为0.99,表明表阿必利标记的是D2位点。体外放射自显影显示,前额叶和扣带回皮质的V层和VI层以及纹状体中受体结合密度很高。体内大鼠脑摄取显示,海马体:小脑和额叶皮质:小脑的比例为2.2:1,氟哌啶醇预处理后该比例降至1.1:1。这些特性表明,[125I]表阿必利是用于体外和体内研究纹状体及纹状体以外多巴胺D2受体的一种优良放射性配体。